Stock Buzzer: Is Buying Bellicum Pharmaceuticals Inc Here a Winning Strategy?

Stock Buzzer: Is Buying Bellicum Pharmaceuticals Inc Here a Winning Strategy?

The stock of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) is a huge mover today! About 360,361 shares traded hands or 54.60% up from the average. Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has risen 81.37% since April 8, 2016 and is uptrending. It has outperformed by 75.72% the S&P500.
The move comes after 7 months positive chart setup for the $607.68M company. It was reported on Nov, 10 by Barchart.com. We have $26.24 PT which if reached, will make NASDAQ:BLCM worth $164.07M more.

Analysts await Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to report earnings on November, 14. They expect $-0.62 earnings per share, down 21.57% or $0.11 from last year’s $-0.51 per share. After $-0.61 actual earnings per share reported by Bellicum Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 1.64% negative EPS growth.

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Ratings Coverage

Out of 7 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), 5 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 71% are positive. Bellicum Pharmaceuticals Inc has been the topic of 10 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The company was maintained on Tuesday, August 9 by Citigroup. The firm has “Buy” rating by Citigroup given on Friday, July 24. The firm earned “Hold” rating on Wednesday, August 19 by Zacks. The company was initiated on Friday, June 3 by SunTrust. The company was initiated on Wednesday, November 2 by Cantor Fitzgerald. On Thursday, February 25 the stock rating was initiated by Citigroup with “Neutral”. The firm has “Buy” rating given on Tuesday, August 9 by Jefferies. As per Friday, September 11, the company rating was upgraded by Guggenheim. Zacks downgraded Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) on Monday, September 21 to “Sell” rating. Suntrust Robinson initiated the stock with “Buy” rating in Friday, June 3 report.

According to Zacks Investment Research, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.”

More notable recent Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) news were published by: Fool.com which released: “Better Buy: Agenus Inc. vs. Bellicum Pharmaceuticals Inc.” on October 18, 2016, also Marketwatch.com with their article: “Bellicum Pharmaceuticals upgraded to buy from neutral at Citigroup” published on December 18, 2014, Fool.com published: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Juno Therapeutics, Inc.” on June 26, 2016. More interesting news about Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) were released by: Fool.com and their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Celldex Therapeutics” published on August 03, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Bellicum Pharmaceuticals Inc.BLCM” with publication date: December 13, 2014.

BLCM Company Profile

Bellicum Pharmaceuticals, Inc., incorporated on July 14, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Firm uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Firm is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. The Company’s CID technologies include CaspaCIDe, CIDeCAR and GoCAR-T.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment